Role of Radical Prostatectomy in the Management of Metastatic Prostate Cancer

  • Hyeong Dong Yuk
  • Cheol KwakEmail author


Most of prostate cancers diagnosed at localized disease were regarded as less aggressive malignancy because of their indolent course; nonetheless, metastatic prostate cancer is still lethal. The 5-year survival rate approaches 100% for patients within localized disease, but it declined to 28% for metastatic disease [1]. About 4% of prostate cancer present metastasis on initial diagnosis, and about one-third of localized prostate cancer patients experience disease progression [2, 3].


  1. 1.
    Metcalfe MJ, Smaldone MC, Lin DW, Aparicio AM, Chapin BF. Role of radical prostatectomy in metastatic prostate cancer: a review. Urol Oncol. 2017;35(4):125–34.CrossRefPubMedGoogle Scholar
  2. 2.
    David N, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67(6):1028–38.CrossRefGoogle Scholar
  3. 3.
    Norum J, Nieder C. Treatments for metastatic prostate cancer (mPC): a review of costing evidence. Pharmacoeconomics. 2017;35:1–14.CrossRefGoogle Scholar
  4. 4.
    Faiena I, Singer EA, Pumill C, Kim IY. Cytoreductive prostatectomy: evidence in support of a new surgical paradigm (review). Int J Oncol. 2014;45(6):2193–8.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–42.CrossRefPubMedGoogle Scholar
  6. 6.
    Eddy C, Guillaume P, Mohamed MD, Vaudoyer D. Management of peritoneal carcinomatosis from colorectal cancer. Cancer J. 2009;15(3):243–8.CrossRefGoogle Scholar
  7. 7.
    Mitchell CR, Boorjian SA, Umbreit EC, Rangel LJ, Carlson RE, Karnes RJ. 20-year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int. 2012;110(11):1709–13.CrossRefPubMedGoogle Scholar
  8. 8.
    Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Elizabeth B, Walsh PC. What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology. 2011;76(3):710–4.CrossRefGoogle Scholar
  9. 9.
    Kane CJ. Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol. 2004;171:668–71.CrossRefPubMedGoogle Scholar
  10. 10.
    Ristau BT, Cahn D, Uzzo RG, Chapin BF, Smaldone MC. The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancer. Future Oncol. 2016;12(5):687–99.CrossRefPubMedGoogle Scholar
  11. 11.
    Kaplan RN, Rafii S, Lyden D. Preparing the “Soil”: the premetastatic niche rosandra. Cancer Res. 2010;66(23):11089–93.CrossRefGoogle Scholar
  12. 12.
    Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet. 2001;358(7):277–86.CrossRefPubMedGoogle Scholar
  13. 13.
    Joniau S, Spahn M, Briganti A, et al. Pretreatment tables predicting pathologic stage of locally advanced prostate cancer. Eur Urol. 2014;67(2):319–25.CrossRefPubMedGoogle Scholar
  14. 14.
    Löppenberg B, Dalela D, Karabon P, et al. The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis. Eur Urol. 2017;72(1):14–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of UrologySeoul National University HospitalSeoulSouth Korea

Personalised recommendations